Please use this identifier to cite or link to this item:
|Title:||Non-Hodgkin Lymphoma after treatment with Extended dosing temozolomide and radiotherapy for a glioblastoma: A case report||Authors:||Van Ginderachter, Laura
|Issue Date:||2013||Source:||Case Report Oncology, 6, p. 45-49||Abstract:||Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy. In addition to the possible mutagenic effect of temozolomide – as described for all alkylating agents – there might have been an immunosuppressive effect of TMZ. The pathological appearance of the lymphoma as well as the presence of a grade 3 lymphopenia early in treatment supports this hypothesis. As the use of TMZ increases, the awareness that TMZ may induce secondary malignancies should increase as well.||Document URI:||http://hdl.handle.net/1942/15103||ISSN:||1662-6575||DOI:||10.1159/000346614||Category:||A2||Type:||Journal Contribution|
|Appears in Collections:||Research publications|
Show full item record
checked on Sep 7, 2020
checked on May 24, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.